Social inequalities in health: How do they influence the natural history of colorectal cancer?

As regards colorectal cancer (CRC) in France, social inequalities in health (SIH) exist. Underprivileged patients are characterized by reduced incidence of CRC and, conversely, by excess mortality. The explanatory mechanisms of the SIHs influencing survival are complex, multidimensional and variable according to healthcare system. Among the most deprived com-pared to the least deprived patients, SIHs are reflected by lower participation in screening campaigns, and CRC diagnosis is more frequently given at a later stage in an emergency con-text. During treatment, disadvantaged patients are more at risk of having to undergo open surgery and of enduring severe postoperative complications and belated chemotherapy (when recommended). Study of SIHs poses unusual challenges, as it is necessary not only to pinpoint social deprivation, but also to locate the different treatment facilities existing in a given terri-torial expanse. In the absence of individualized socioeconomic information, research in France on the social determinants of health is based on duly constituted cancer registries, in which an ecological index of social deprivation, the European Deprivation Index (EDI), provides an aggre-gate measure of the socioeconomic environment of a given individual in a given geographical setting at a given point in time. All in all, studies on SIHs are justified as means of identification and comprehension of the mechanisms underlying social deprivation, the objective being to more precisely orient programs and practices aimed at combating SIH.& COPY; 2023 Elsevier Masson SAS. All rights reserved.

Automated summary

In France, there are social inequalities in health for patients with colorectal cancer (CRC). Underprivileged patients have a lower incidence of CRC but higher mortality rates. The reasons behind these social inequalities vary depending on the healthcare system. Factors such as reduced participation in screening campaigns and delayed diagnosis contribute to the disparities in survival rates. Disadvantaged patients also face challenges during treatment, including a higher risk of open surgery, severe complications, and delayed chemotherapy.